ROBERT CANTU: Open Payments
NPI 1891771499 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$831 in 28 payments from 7 companies in 2025. Trend: 2023 $1,242 · 2024 $876 · 2025 $831
Food & beverage: $831
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $247 |
| ABBVIE INC. | 6 | $191 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| Lilly USA, LLC | 1 | $94 |
| Axsome Therapeutics, Inc. | 4 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: CAPLYTA, VRAYLAR, REXULTI, ZEPBOUND, Auvelity, TRINTELLIX, COBENFY.
Industry payments across TX — which companies pay providers there.
